Logo
DISOLVIDASE 5 Pack (5 x 1500 I.U. Vials)

DISOLVIDASE 5 Pack (5 x 1500 I.U. Vials)

Dermaqual

Aesthetic Injectables
  • Manufactured under Dermaqual’s quality management systems applicable to aesthetic and mesotherapy products.
  • Regulatory status (e.g. cosmetic/aesthetic agent versus medicinal product) may vary by country; practitioners must verify and comply with local regulatory and prescribing requirements before use.
Hyaluronidase filler dissolver

Description

DISOLVIDASE 5 Pack is a boxed presentation of Dermaqual’s hyaluronidase-based hyaluronic acid hydrolyser, formulated as a white, sterile, freeze-dried (meso-lyophilised) powder for solution. Each of the 5 vials contained in the box has 1,500 international units (I.U.) of hyaluronidase intended to be reconstituted, typically to a 10 ml solution, for professional injectable use. The product enzymatically degrades hyaluronic acid (HA) by depolymerising HA chains and disrupting cross-links, accelerating the breakdown and clearance of HA from tissues. It is used by qualified healthcare professionals to dissolve or reduce unwanted HA dermal fillers, treat uncomplicated and inflamed nodules, manage overcorrection and support protocols for tissue ischaemia secondary to HA injection, as well as in certain mesotherapy/body-contouring protocols such as hydrolipodystrophy (cellulite) grades III–IV.

Bnefits

  • Specifically targets hyaluronic acid-based dermal fillers, allowing controlled dissolution of unwanted or excessive filler material.
  • Helps correct aesthetic complications such as overcorrection, lumps, bumps and nodules following HA filler injections.
  • Supports emergency management protocols for HA-related vascular compromise and tissue ischaemia by rapidly degrading obstructive HA deposits (within appropriate clinical guidelines).
  • Increases tissue permeability and facilitates the spread and diffusion of other injected solutions in mesotherapy and aesthetic treatments.
  • Supplied as a highly purified, sterile, freeze-dried powder for accurate reconstitution and dosing by trained clinicians.
  • Box of 5 vials provides convenient multi-treatment supply while maintaining single-patient sterility at the vial level.
  • Visible clinical improvements with hyaluronidase are typically observed within 24–48 hours, with full effects usually by around 72 hours after treatment when appropriately dosed.
  • Formulated and presented specifically for professional aesthetic use in managing HA filler outcomes and selected cellulite/body-contouring indications.

Indications

  • Enzymatic degradation of hyaluronic acid dermal fillers where reduction or removal is desired due to unsatisfactory aesthetic outcome.
  • Treatment of uncomplicated nodules, lumps, overcorrection and irregularities created by HA filler injection.
  • Supportive use in the management of inflamed nodules associated with HA fillers as part of a wider complication-management protocol.
  • Adjunctive management of suspected tissue ischaemia or vascular compromise due to HA filler, following recognised aesthetic emergency guidelines and clinician judgement.
  • Use in body-contouring and cellulite protocols (e.g. hydrolipodystrophy grade III and IV) as part of professional mesotherapy treatment plans.
  • Increasing tissue permeability and enhancing diffusion of other active injectable substances when clinically appropriate in mesotherapy/aesthetic medicine.

Composition

  • Hyaluronidase 1,500 I.U. per vial (lyophilised powder).
  • Mannitol (stabilising excipient).
  • Other inactive excipients as specified in the manufacturer’s full product information.
  • Aqua / Water for injection is used for reconstitution (not supplied in all packs; supplied separately according to local practice).

Formulation

  • White, sterile, freeze-dried (meso-lyophilised) powder for solution for injection / mesotherapy.
  • Each vial is intended to be reconstituted to a specified volume (commonly 10 ml) to yield a solution containing a total of 1,500 I.U. hyaluronidase.
  • Intended exclusively for professional use by appropriately qualified healthcare practitioners experienced in injectable aesthetic treatments and complication management.

Packaging

  • Cardboard box containing 5 sterile glass vials of DISOLVIDASE, each vial with 1,500 I.U. hyaluronidase as a solid lyophilised powder.
  • Each vial is individually sterile and intended for single-patient use only.
  • Outer packaging labelled with product name, batch number, expiry date, manufacturer details and basic directions in accordance with local regulatory requirements.

Usage

  • DISOLVIDASE must only be used by suitably trained and qualified healthcare professionals (e.g. aesthetic doctors, prescribing practitioners) familiar with hyaluronidase and dermal filler complication management.
  • Before use, inspect the vial to confirm integrity of the glass and closure, and verify that the product is within its expiry date.
  • Reconstitute the lyophilised powder in each vial with a suitable sterile diluent (commonly 0.9% sodium chloride for injection) in the volume recommended by the manufacturer or local protocol, using strict aseptic technique.
  • Gently swirl the vial to fully dissolve the powder; do not vigorously shake to avoid foaming. Inspect the solution to ensure it is clear and free of visible particulates.
  • Determine dosage, injection depth, and injection technique based on the clinical indication (e.g. superficial nodules, deep filler bolus, suspected vascular event) and current evidence-based aesthetic guidelines.
  • Inject into or around the area of HA filler to be dissolved, avoiding intravascular injection by following safe injection practices, aspiration as indicated, and appropriate anatomical knowledge.
  • Monitor the patient closely during and after the procedure for local and systemic reactions, particularly signs of hypersensitivity, and be prepared to manage adverse events including anaphylaxis as per emergency protocols.
  • Use reconstituted solution promptly; if storage after reconstitution is permitted under local guidelines or manufacturer instructions, adhere strictly to the specified time and conditions, and discard any unused solution thereafter.
  • Vials are single-use; do not reuse leftover solution on another patient. Dispose of sharps and unused product according to clinical waste regulations.
  • Avoid patient self-administration and ensure that treatment is performed in a clinical setting equipped to handle complications.

Contraindications

  • Known hypersensitivity or allergy to hyaluronidase or any of the excipients (e.g. mannitol).
  • History of severe allergic or anaphylactic reactions that may be triggered or exacerbated by hyaluronidase, as judged by the treating clinician.
  • Active local infection, inflammation or open wounds at the intended injection site.
  • Use in patients for whom invasive aesthetic procedures are contraindicated due to significant comorbidities, medications or unstable medical conditions, unless justified and carefully monitored by a medical professional.
  • Use during pregnancy or breastfeeding is generally not recommended in the absence of adequate safety data; clinicians should follow local regulations and professional guidance.

Adverse Effects

  • Local injection-site reactions including pain, tenderness, erythema, swelling, pruritus and bruising.
  • Transient oedema and softening of tissues associated with rapid degradation of hyaluronic acid.
  • Occasional urticaria or other hypersensitivity-type skin reactions.
  • Rare but potentially serious systemic allergic reactions, including anaphylaxis; emergency equipment and medication must be available.
  • Overcorrection or unintended dissolution of desirable hyaluronic acid filler if dose, placement or indication are not carefully planned.
  • General risks associated with injection procedures, such as infection, bleeding, haematoma and, if technique is poor or anatomy not respected, tissue damage or vascular complications.

Storage Conditions

  • Store unopened vials in a cool, dry place at the temperature range stated on the packaging (typically controlled room temperature).
  • Keep vials in their original outer carton to protect from light until the time of use.
  • Do not freeze and do not expose to excessive heat or direct sunlight.
  • Do not use after the expiry date printed on the vial and carton.
  • After reconstitution, follow any manufacturer or local protocol guidance on allowable storage time and conditions; if not used within the specified time, discard the solution safely.
  • Keep out of the sight and reach of children.

Duration

Typically administered as a single treatment session or a short series of sessions until the desired reduction of hyaluronic acid filler or clinical effect is achieved; exact number and frequency of sessions are determined by the treating healthcare professional based on patient response and clinical guidelines.

Onset

Clinical softening and reduction of hyaluronic acid filler often begins within hours, with visible improvement generally reported within 24\u201348 hours and maximal effect usually observed by approximately 72 hours after treatment.

Browse more Aesthetic Injectables

Top Treatments

Top Cities in the UK